HLS HLS Therapeutics Inc
- 3.870
- +0.120+3.20%
HLS Therapeutics Inc News
HLS Therapeutics Inc (HLTRF) Q3 2024 Earnings Call Highlights: Strategic Debt Reduction and ...
HLS Therapeutics Q2 Net Loss Narrows With Cut in Expenses, Revenue Falls
Press Release: HLS Therapeutics Announces Q2 2024 Financial Results
Strategic Divestiture and Financial Flexibility: HLS Therapeutics Inc's Optimistic Buy Rating
Stifel Nicolaus Keeps Their Hold Rating on HLS Therapeutics Inc (HLS)
Stocks in Play: HLS Therapeutics Inc.
New Study Published on the Impact of Pharmaceutical Support Programs on Persistence With Clozapine Treatment
HLS Therapeutics Meets Q1 Earnings Forecast, But Misses on Revs; Lowers 2024 Vascepa Guidance
HLS Therapeutics Inc: INTERIM MDA EN
HLS Therapeutics Inc: INTERIM FINANCIAL STATEMENTSREPORT EN
Press Release: HLS Therapeutics to Host Q1 Fiscal 2024 Financial Results Conference Call
HLS Therapeutics Inc: AUDITED ANNUAL FINANCIAL STATEMENTS AMENDED EN
HLS Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
HLS Therapeutics Inc Price Target Cut to C$5.00/Share From C$6.50 by Raymond James
Earnings Release: Here's Why Analysts Cut Their HLS Therapeutics Inc. (TSE:HLS) Price Target To CA$6.57
HLS Therapeutics Inc Price Target Cut to C$4.15/Share From C$4.35 by Stifel Nicolaus
HLS Therapeutics Inc. (TSE:HLS) Stock Most Popular Amongst Retail Investors Who Own 40%, While Hedge Funds Hold 39%
HLS Therapeutics Reports Q4 2023 Net Loss of US$5.4 Million; Provides 2024 Outlook, Credit Agreement Update
HLS Therapeutics Inc: MDA EN
HLS Therapeutics Inc: AUDITED ANNUAL FINANCIAL STATEMENTS EN
No Data